2020 has been a year in which anything associated with medicine and biotech assumed critical importance. GESSEL was well placed to respond to these extraordinary needs by drawing on its robust experience in these sectors.

For years, GESSEL is proud to count among its Clients the LUX MED Group, a leader in the Polish private healthcare sector, and Polski Bank Komórek Macierzystych S.A., member of the FamiCord Group – operator of stem cell banks around Europe and in Turkey. 2020 brought opportunities to write new chapters in these longstanding cooperations.

We also advised Black Forest, an investment fund owned by Michał Sołowow, on an investment in ExploRNA, a research entity developing genetic technologies of the kind underpinning newest generation vaccines and holding much promise for individualised cancer treatments, and the Sunfish Partners fund on an investment in Aether Biomedical, active in medical robotics.

A lawyer called upon to advise on a deal involving a biotech entity must not only be well phrased in the legal aspects of the transaction, but also have at least a rudimentary understanding of the science involved, keeping an open mind to specialised knowledge from entirely different fields. In this spirit, GESSEL’s multidisciplinary team has been able to support our Clients not only with the deal structure in the strict sense, but also with the intellectual property dimensions and in medical law. I am proud to say that we have developed a bit of a grounding in biotech, enabling us to better address the expectations and needs of Clients investing in this dynamically evolving area.

Maciej Kożuchowski, partner, GESSEL